Dosimetry-personalised PRRT instead of four fixed cycles
Measure the radiation each patient's tumour and kidneys actually absorb and adjust the number and size of doses, instead of giving everyone four identical cycles.
Fixed 7.4 GBq × 4 leaves many patients under-dosed relative to kidney and marrow limits; retrospective dosimetry shows tumour absorbed dose correlates with response. Prospective trials (e.g., P-PRRT in Canada) test individualised activity.
Pages like this
not linked directly; found by shared links- PairingSSTR PET → PRRT
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Neuroendocrine tumours.
- TrialCOMPETE
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Neuroendocrine tumours.
- CompanyITM Isotope Technologies Munich
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Neuroendocrine tumours.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares Peptide receptor radionuclide therapy (PRRT), Neuroendocrine tumours.
- IdeaTotal-body PET for personalised radioligand dosing
Shares SPECT & bone scan, Dosimetry, Wrong doses.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Peptide receptor radionuclide therapy (PRRT), Dosimetry, Neuroendocrine tumours.
- TechnologySomatostatin receptor PET (68Ga/64Cu-DOTATATE)
Shares Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Neuroendocrine tumours.
- CompanyRayzeBio (BMS)
Shares Peptide receptor radionuclide therapy (PRRT), Neuroendocrine tumours.